NSCLC: medial segment right-lobe lung tumors yield worse OS

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients with NSCLC in the medial segment of the right lobe fare worse than patients with tumors in any other location.

Why this matters

  • Patients with medial segment tumors were also more likely to have mediastinal metastasis.

Study design

  • 711 patients with stage I NSCLC underwent lobectomy or bilobectomy with systemic lymph node dissection with a median follow-up of 52.3 months.
  • Funding: None disclosed.

Key results

  • Among patients with right lobe tumors, 39 had tumors in the medial segment and 43 in the lateral segment.
  • Similar 5-year OS and recurrence-free survival (RFS) between patients with right middle lobe tumors and patients with tumors in other lobes (79.7% vs 82.2%; P=.23 and 67.0% vs 71.4%; P=.19, respectively).
  • Patients with medial segment tumors had significantly worse 5-year OS and RFS than those with tumors in the lateral segment (69.8% vs 87.6%; P=.040 and 58.4% vs 73.0%; P=.029, respectively).
  • Prognosis was significantly worse for patients with medial segment tumors compared with other lobe tumors (5-year OS: 69.8% vs 82.2%; P=.020 and 5-year RFS: 58.4% vs 71.4%; P=.0071).
  • Mediastinal lymph node metastasis more common in patients with medial segment tumors compared with lateral segment tumors (12.8% vs 2.3%; P=.097).

Limitations

  • Retrospective study.